Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Labskin Limited
Deal Size : $2.0 million
Deal Type : Collaboration
Genvira and Labskin Receive £1.2 Million UK–Canada Collaboration Award
Details : As part of the collaboration, Labskin will utilize its expertise in advanced disease modeling to develop a novel 3D human skin model of melanoma, enabling in vitro testing of vaccine candidates.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
July 31, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Labskin Limited
Deal Size : $2.0 million
Deal Type : Collaboration